Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;69(5):2150-2163.
doi: 10.1002/hep.30494. Epub 2019 Mar 20.

Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis

Affiliations

Incidence and Mortality of Acute-on-Chronic Liver Failure Using Two Definitions in Patients with Compensated Cirrhosis

Nadim Mahmud et al. Hepatology. 2019 May.

Abstract

The term acute-on-chronic liver failure (ACLF) is intended to identify patients with chronic liver disease who develop rapid deterioration of liver function and high short-term mortality after an acute insult. The two prominent definitions (European Association for the Study of the Liver [EASL] and Asian Pacific Association for the Study of the Liver [APASL]) differ, and existing literature applies to narrow patient groups. We sought to compare ACLF incidence and mortality among a diverse cohort of patients with compensated cirrhosis, using both definitions. This was a retrospective cohort study of patients with incident compensated cirrhosis in the Veterans Health Administration from 2008 to 2016. First ACLF events were identified for each definition. Incidence rates were computed as events per 1,000 person-years, and mortality was calculated at 28 and 90 days. Among 80,383 patients with cirrhosis with 3.35 years median follow-up, 783 developed EASL and APASL ACLF, 4,296 developed EASL ACLF alone, and 574 developed APASL ACLF alone. The incidence rate of APASL ACLF was 5.7 per 1,000 person-years (95% confidence interval [CI]: 5.4-6.0), and the incidence rate of EASL ACLF was 20.1 (95% CI: 19.5-20.6). The 28-day and 90-day mortalities for APASL ACLF were 41.9% and 56.1%, respectively, and were 37.6% and 50.4% for EASL ACLF. The median bilirubin level at diagnosis of EASL-alone ACLF was 2.0 mg/dL (interquartile range: 1.1-4.0). Patients with hepatitis C or nonalcoholic fatty liver disease had among the lowest ACLF incidence rates but had the highest short-term mortality. Conclusion: There is significant discordance in ACLF events by EASL and APASL criteria. The majority of patients with EASL-alone ACLF have preserved liver function, suggesting the need for more liver-specific ACLF criteria.

PubMed Disclaimer

Conflict of interest statement

Author Disclosures

We confirm that none of the authors have any conflicts of interest or other relevant disclosures pertaining to this manuscript.

Figures

Figure 1 –
Figure 1 –
ACLF Events over Time per APASL (a) and EASL (b) Criteria - The probability of experiencing an ACLF event over time was significantly higher for patients with either alcoholic or hepatitis C plus alcoholic liver disease, as compared to other etiologies of liver disease. This was true in both APASL and EASL ACLF definitions.
Figure 1 –
Figure 1 –
ACLF Events over Time per APASL (a) and EASL (b) Criteria - The probability of experiencing an ACLF event over time was significantly higher for patients with either alcoholic or hepatitis C plus alcoholic liver disease, as compared to other etiologies of liver disease. This was true in both APASL and EASL ACLF definitions.
Figure 2 –
Figure 2 –
ACLF Survival over Time for APASL (a) and EASL (b) Events – The probability of ACLF survival was significantly lower through one year for patients with hepatitis C or non-alcoholic fatty liver disease, as compared to other etiologies of liver disease. This was true in both APASL and EASL ACLF definitions.
Figure 2 –
Figure 2 –
ACLF Survival over Time for APASL (a) and EASL (b) Events – The probability of ACLF survival was significantly lower through one year for patients with hepatitis C or non-alcoholic fatty liver disease, as compared to other etiologies of liver disease. This was true in both APASL and EASL ACLF definitions.
Figure 3 –
Figure 3 –
Frequency of Organ Failures and Acute Decompensations in EASL ACLF. Kidney failure was the most common organ failure among all EASL ACLF grades (a), while infection was the most common acute decompensation in EASL grades 1 and 3 (b). Among patients EASL ACLF grade 3, kidney was the most common organ failure (c) and infection the most common acute decompensation (d) for all etiologies of liver disease.
Figure 3 –
Figure 3 –
Frequency of Organ Failures and Acute Decompensations in EASL ACLF. Kidney failure was the most common organ failure among all EASL ACLF grades (a), while infection was the most common acute decompensation in EASL grades 1 and 3 (b). Among patients EASL ACLF grade 3, kidney was the most common organ failure (c) and infection the most common acute decompensation (d) for all etiologies of liver disease.
Figure 3 –
Figure 3 –
Frequency of Organ Failures and Acute Decompensations in EASL ACLF. Kidney failure was the most common organ failure among all EASL ACLF grades (a), while infection was the most common acute decompensation in EASL grades 1 and 3 (b). Among patients EASL ACLF grade 3, kidney was the most common organ failure (c) and infection the most common acute decompensation (d) for all etiologies of liver disease.
Figure 3 –
Figure 3 –
Frequency of Organ Failures and Acute Decompensations in EASL ACLF. Kidney failure was the most common organ failure among all EASL ACLF grades (a), while infection was the most common acute decompensation in EASL grades 1 and 3 (b). Among patients EASL ACLF grade 3, kidney was the most common organ failure (c) and infection the most common acute decompensation (d) for all etiologies of liver disease.

Comment in

References

    1. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. Journal of hepatology 2006;44:217–231. - PubMed
    1. Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Medical Clinics 2009;93:787–799. - PubMed
    1. Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. Journal of hepatology 2014;61:1038–1047. - PubMed
    1. Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013;144:1426–1437.e9. - PubMed
    1. Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatology international 2014;8:453–471. - PubMed

Publication types